ERBB2 and breast cancer: Moreover, 65% of Yo-PCD tumors had at least one somatic mutation in the Yo-antigen genes, mainly missense mutations, compared to the control group.462 In patients with breast cancer combined with Yo-PCD, these breast cancers were predominantly aggressive, HER2-positive, and hormone receptor-negative, with early lymph node metastasis.